Eli Lilly, Merck Lead Market Cap Stock Movers on Wednesday…
Pharmaceutical stocks gained Wednesday afternoon amid anticipation Pfizers deal with the Trump administration could lead to more with other firms.…
…
The pharmaceutical company had a clinical setback earlier this year, but thats now in the rearview mirror.…
Eli Lilly secures EU approval for Alzheimers drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.…
…
Bloomberg journalists discuss todays biggest winners and losers in the stock market. Listen for analysis on the companies making news…
Eli Lillys diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the obesity…
In the closing of the recent trading day, Eli Lilly (LLY) stood at $746.98, denoting a -1.06% move from the…
More production capacity for the obesity pill is crucial as Eli Lilly races to bring it to market and tries…
Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC…
Apple grows Services with over 1B subscribers, while Eli Lilly and Chevron face mixed industry and market dynamics.…
…
Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according…
The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment…
Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling…
The FDAs warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss…
The U.S. Food and Drug Administration’s recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment…
Eli Lillys orforglipron beat NVOs Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.…
HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat Eli Lilly von "Buy" auf "Hold" abgestuft…
Die Aktie von Eli Lilly (NYSE: LLY) legte am Dienstag deutlich zu und gewann im Tagesverlauf bis zu 5,9 %. Auslöser war die…
Nach der Veröffentlichung enttäuschender Studiendaten erholt sich die Aktie von Eli Lilly langsam wieder. Die neue Abnehmpille Orforglipron von Eli…
The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight…
Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive…
The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight…
A new, late-stage clinical study shows disappointing results for Eli Lillys weight loss pill Orforglipron. The experimental drug has less…
Shares of rival Novo Nordisk rose as both companies develop weight loss pills.…
Here are some of the stocks posting the biggest moves in midday trading.…
Here are some of the stocks posting the biggest moves in midday trading.…
Weight-loss drugs are expected to pull in more than $150 billion in industry-wide revenue by the early 2030s, thanks to…
These are the stocks posting the largest moves in premarket trading.…
Eli Lillys pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for…
…
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight…
Eli Lilly hat neue Studienergebnisse zum oralen GLP?1-Kandidaten Orforglipron vorgelegt. In einer Phase?III-Studie verloren übergewichtige Teilnehmer ohne Diabetes innerhalb von…
Stock Market Today: The Dow Jones Index rose Thursday on Trump tariff news. Eli Lilly plunged on disappointing weight-loss drug…
Shares in Novo Nordisk rose 13.6% on Thursday after trial data from Eli Lillys experimental weight-loss pill fell short of…
Novo Nordisk shares jump as Eli Lilly obesity pill disappoints…
Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug,…
Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as…
Paukenschlag im Adipositas-Markt: Das US-amerikanische Pharma-Unternehmen Eli Lilly hat neben den erwarteten Zahlen zum zweiten Quartal frische Studiendaten zur Abnehm-Pille…
…
Eli Lilly and Co (NYSE:LLY) shares fell more than 10% at the market open as disappointing late-stage trial data for…
Dow, S&P 500, and Nasdaq futures are rising in premarket trading as the stock market digests President Donald Trumps reciprocal…
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after…
Wall Street is optimistic heading into Eli Lillys second-quarter earnings report.…
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy obesity drug,…
Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue…
Disney and Eli Lilly are among the six Club stocks reporting in the coming days.…